RWA Wealth Partners LLC Grows Stock Holdings in Biohaven Ltd. (NYSE:BHVN)

RWA Wealth Partners LLC grew its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 81.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,800 shares of the company’s stock after purchasing an additional 5,300 shares during the quarter. RWA Wealth Partners LLC’s holdings in Biohaven were worth $441,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. HighTower Advisors LLC increased its stake in Biohaven by 6.1% in the fourth quarter. HighTower Advisors LLC now owns 5,870 shares of the company’s stock valued at $219,000 after purchasing an additional 335 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Biohaven by 0.5% during the 3rd quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock worth $4,206,000 after acquiring an additional 412 shares during the period. FSC Wealth Advisors LLC boosted its position in shares of Biohaven by 3.3% in the fourth quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company’s stock worth $579,000 after acquiring an additional 500 shares during the last quarter. Prudential Financial Inc. grew its holdings in Biohaven by 9.4% in the fourth quarter. Prudential Financial Inc. now owns 5,980 shares of the company’s stock valued at $223,000 after purchasing an additional 514 shares during the period. Finally, Amalgamated Bank increased its position in Biohaven by 21.9% during the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock worth $109,000 after purchasing an additional 527 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Analysts Set New Price Targets

BHVN has been the subject of several research reports. JPMorgan Chase & Co. lowered their price objective on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft set a $60.00 price target on Biohaven and gave the stock a “buy” rating in a research note on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $54.00 price objective on shares of Biohaven in a research note on Tuesday, March 4th. Morgan Stanley dropped their target price on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Fourteen equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $62.77.

Insider Buying and Selling at Biohaven

In related news, Director John W. Childs acquired 32,700 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was bought at an average cost of $30.47 per share, with a total value of $996,369.00. Following the acquisition, the director now directly owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 16.00% of the stock is currently owned by corporate insiders.

Biohaven Price Performance

Biohaven stock opened at $22.60 on Wednesday. The firm’s fifty day moving average price is $34.55 and its 200 day moving average price is $41.21. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of -2.42 and a beta of 1.27. Biohaven Ltd. has a 12-month low of $21.47 and a 12-month high of $55.72.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.